Title : Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice - Rasmussen_2000_Eur.J.Pharmacol_402_241 |
Author(s) : Rasmussen T , Sauerberg P , Nielsen EB , Swedberg MD , Thomsen C , Sheardown MJ , Jeppesen L , Calligaro DO , DeLapp NW , Whitesitt CA , Ward JS , Shannon HE , Bymaster FP , Fink-Jensen A |
Ref : European Journal of Pharmacology , 402 :241 , 2000 |
Abstract :
(5R,6R)-6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[ 3.2.1]octane (PTAC) is a selective muscarinic receptor ligand. The compound exhibits high affinity for central muscarinic receptors with partial agonist mode of action at muscarinic M(2) and M(4) and antagonist mode of action at muscarinic M(1), M(3) and M(5) receptor subtypes. The compound was earlier reported to exhibit functional dopamine receptor antagonism in rodents despite its lack of affinity for dopamine receptors. In the present study, we report that PTAC, as well as the muscarinic receptor agonists pilocarpine and oxotremorine, dose-dependently decreased rates of intravenous self-administration (fixed ratio 1) of the indirect dopamine receptor agonist cocaine in drug naive mice. Similar decreases in cocaine self-administration rates were obtained with the dopamine receptor antagonists olanzapine, clozapine, risperidone, fluphenazine and haloperidol. These findings suggest that compounds with partial muscarinic receptor agonist mode of action may be used in the medical treatment of cocaine abuse. |
PubMedSearch : Rasmussen_2000_Eur.J.Pharmacol_402_241 |
PubMedID: 10958890 |
Rasmussen T, Sauerberg P, Nielsen EB, Swedberg MD, Thomsen C, Sheardown MJ, Jeppesen L, Calligaro DO, DeLapp NW, Whitesitt CA, Ward JS, Shannon HE, Bymaster FP, Fink-Jensen A (2000)
Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice
European Journal of Pharmacology
402 :241
Rasmussen T, Sauerberg P, Nielsen EB, Swedberg MD, Thomsen C, Sheardown MJ, Jeppesen L, Calligaro DO, DeLapp NW, Whitesitt CA, Ward JS, Shannon HE, Bymaster FP, Fink-Jensen A (2000)
European Journal of Pharmacology
402 :241